CJEU AG’s Opinion in Santen referral proposes to abandon Neurim

On 23 January 2020, AG Giovanni Pitruzzella provided his Opinion on the interpretation of Article 3(d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products ("SPC Regulation"). In doing so, AG Pitruzzella makes two proposals to the CJEU. His favoured proposal would significantly curtail the availability of SPCs for second medical uses of known and previously authorised compounds, as it strictly interprets the meaning of "product" under Article 1(b) and precludes an interpretation of Neurim according to which a marketing authorisation (“MA”) for a “different and new application of an old active ingredient” could be considered as the first MA of a previously authorised active ingredient. His alternative proposal permit SPCs in a wider set of circumstances by interpreting Neurim as allowing an SPC to be granted if the new MA “covers a new therapeutic indication of said active ingredient or relates to a use of it in which this active ingredient exerts a new pharmacological, immunological or metabolic action of its own”. Read more

European pharma patent law update

Hear the latest developments in European pharmaceutical patent law from France, Italy and the UK. Now available on demand. Key topics included: The situation of provisional damages in PI proceedings and the consequences in terms of damages of a wrongly awarded PI in France and Italy The implications of the above with respect to involving … Read more

Harnessing the power of diversity in IP

On Thursday 7 November, our London IP team hosted a panel discussion and roundtable session on 'Harnessing the power of diversity in IP'. This was part of an ongoing campaign with World IP Review (WIPR), to celebrate the achievements of influential women in IP and to improve gender diversity in the profession. Read more